Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Payables (2018 - 2026)

TransMedics has reported Payables over the past 8 years, most recently at $10.4 million for Q4 2025.

  • For Q4 2025, Payables rose 0.56% year-over-year to $10.4 million; the TTM value through Dec 2025 reached $10.4 million, up 0.56%, while the annual FY2025 figure was $10.4 million, 0.56% up from the prior year.
  • Payables for Q4 2025 was $10.4 million at TransMedics, down from $12.2 million in the prior quarter.
  • Over five years, Payables peaked at $13.1 million in Q3 2024 and troughed at $1.3 million in Q1 2021.
  • A 5-year average of $7.7 million and a median of $8.1 million in 2023 define the central range for Payables.
  • On a YoY basis, Payables climbed as much as 451.49% in 2021 and fell as far as 73.48% in 2021.
  • Year by year, Payables stood at $6.7 million in 2021, then crashed by 49.77% to $3.3 million in 2022, then surged by 280.63% to $12.7 million in 2023, then fell by 19.07% to $10.3 million in 2024, then rose by 0.56% to $10.4 million in 2025.
  • Business Quant data shows Payables for TMDX at $10.4 million in Q4 2025, $12.2 million in Q3 2025, and $9.5 million in Q2 2025.